-
subsidiaries Genmab B.V. in Utrecht, the Netherlands,
Genmab U.S., Inc. in Princeton, New Jersey, US, and
Genmab K.K. in Tokyo, ****an.
Genmab is
listed on...
- cells.
Daratumumab was
originally developed by
Genmab, but it is now
being jointly developed by
Genmab along with the
Johnson &
Johnson subsidiary Janssen...
-
leukemia (CLL) in the
United States. It is sold by
Novartis under license from
Genmab. The most
common side
effects for
ofatumumab (Kesimpta)
include upper respiratory...
- co-developed with
Astellas Pharma,
tisotumab vedotin,
being co-developed with
Genmab, SGN-LIV1A, an ADC
targeting LIV-1, and
several immuno-oncology
agents in...
- CD20-directed CD3 T-cell engager.
Epcoritamab was co-developed by
AbbVie and
Genmab.
Epcoritamab was
approved for
medical use in the
United States in May 2023...
-
companies Denmark A.P. Møller
Maersk Carlsberg Coloplast Danske Bank DSV
Genmab Novo
Nordisk Novonesis (Novozymes) Ørsted
Pandora Vestas Wind
Systems Zealand...
- epcoritamab, a blood-cancer
therapy under development in
partnership with
Genmab. The name "AbbVie" is
derived from a
combination of "Abbott", the name of...
-
companies Denmark A.P. Møller
Maersk Carlsberg Coloplast Danske Bank DSV
Genmab Novo
Nordisk Novonesis (Novozymes) Ørsted
Pandora Vestas Wind
Systems Zealand...
-
following the last dose. It is a
human monoclonal antibody developed by
Genmab and
Roche for
tumour treatment but was
later researched by
River Vision...
-
companies Denmark A.P. Møller
Maersk Carlsberg Coloplast Danske Bank DSV
Genmab Novo
Nordisk Novonesis (Novozymes) Ørsted
Pandora Vestas Wind
Systems Zealand...
